Joint conference on Equitable, integrative, and value-driven digital health transformation

SPEAKER

Dr. Juan Carlos Rejon-Parrilla 

Senior researcher at the Andalusian Health Technology Assessment Unit (AETSA)

 

Juan Carlos Rejon-Parrilla is a researcher based at the Andalusian Health Technology Assessment department (AETSA), and holds a PhD in health economics (University of Granada, Spain), an MSc in Health Economics, Policy and Law (Erasmus University, Rotterdam, The Netherlands) and a degree in Pharmacy (University of Sevilla, Spain).

Juan Carlos has developed most of his career working in the interface between health technology assessment (HTA)-oriented research and policy. Before joining AETSA, he held a position at the research arm of the National Institute for Health and Care Excellence (NICE).

In both HTA institutions, he has been highly exposed to working across topics, teams and projects, providing him with a deep understanding of the most current methodological challenges that regional, national and international research initiatives try to address to equip decision makers with responsibilities over access to health technologies with new and improved tools.

Previous roles include a position as health economist at the Office of Health Economics (OHE) and as a role as freelance researcher for the Royal College of Nursing (RCN).

Throughout his career, he has had the opportunity of working with a range of stakeholders, including charities, academic leaders, regulatory authorities, industry and other national and international partners in the context of national research projects, the Innovative Medicines Initiative (IMI), Horizon 2020 and Horizon Europe proposals and projects.

He has participated in research initiatives on a wide range of topics within the HTA space and its interface with the regulatory environment and pricing and reimbursement policy, including (but not limited to) fields like personalised medicine and advanced therapy medicinal products (ATMPs), digital health technologies, high-risk medical devices and the use of real-world evidence to support decision making.